MET and cancer: Differently from the context of ‘oncogene addiction’—where aberrant receptor signaling originates from a genetic lesion and drives cancer initiation—here, wild-type MET activation represents a strategy harnessed by otherwise transformed tumor cells to overcome barriers to their progression and to boost their malignant phenotype.